| 摘要: |
| 目的:分析我院门诊患儿盐酸哌甲酯缓释片应用现状,并评价其用药合理性。 方法:回顾性选取我院2024 年7 月至2025 年 6 月盐酸哌甲酯缓释片门诊处方,统计患儿性别、年龄、用法用量及用药时间等临床资料,依据相关法律法规审核处方合理性, 并以儿童限定日剂量(cDDD)和儿童药物利用指数(cDUI)等指标评估合理用药情况。 结果:共收集处方 13 697 张,其中男女患 儿处方比例为 5. 16 ∶ 1,6~9 岁患儿占比最高(39. 35%)。 使用盐酸哌甲酯缓释片的患儿中,5 ~ <8 岁组及 8 ~ <15 岁组的 cDUI 分别为 1. 26 和 1. 12,表明用药剂量偏大。 不合理处方共 225 张。 结论:我院盐酸哌甲酯缓释片的应用基本合理,5 ~ <8 岁及 8~ <15 岁年龄组剂量普遍偏大,且处方质量仍有待提高。 应强化医师及药师培训,加快建立“疗效-剂量-安全性”多维评价体 系,进一步保障临床用药安全。 |
| 关键词: 盐酸哌甲酯缓释片 注意缺陷多动障碍 处方 合理性 儿童药物利用指数 |
| DOI：10.13407/j.cnki.jpp.1672-108X.2026.06.011 |
|
| 基金项目:上海吴孟超医学科技基金会—广东省药学会外科药学曼陀罗研究专项,编号 2022WKYX02 |
|
| Rationality Analysis of Prescription for Methylphenidate Hydrochloride Extended-Release Tablets in Pediatric Outpatient Department: Based on a Single-Center Retrospective Study |
| Duan Shuni, He Yongyang, Chen Jie, Jin Guanglei, Tang Chunze, Li Xuejuan, Yang Ling, Chen Zebin |
| (Shenzhen Children’s Hospital, Guangdong Shenzhen 518026, China) |
| Abstract: |
| Objective: To analyze the current application status of methylphenidate hydrochloride extended-release tablets in pediatric outpatients of our hospital and evaluate the application rationality. Methods: Retrospective analysis was conducted on all outpatient prescriptions for methylphenidate hydrochloride extended-release tablets dispensed from Jul. 2024 to Jun. 2025, clinical data such as gender, age, usage and dosage and treatment duration were statistically analyzed. The rationality of prescriptions were reviewed according to relevant laws and regulations. Drug utilization was further assessed by using the children’s defined daily dose (cDDD) and the children’s drug utilization index ( cDUI). Results: A total of 13,697 prescriptions were extracted, the male-to-female ratio was 5. 16 ∶ 1, and children aged from 6 to 9 years took the lead (39. 35%). Among the children receiving methylphenidate hydrochloride extended-release tablets, the cDUI values were respectively 1. 26 and 1. 12 in the 5 to < 8 years group and 8 to < 15 years group, indicating the doses were above the recommended level. Besides, 225 prescriptions were classified as irrational. Conclusion: Overall application of methylphenidate hydrochloride extended-release tablets in our hospital is generally appropriate, yet doses tend to exceed the recommended level in children aged 5 to <8 and 8 to <15 years, and prescription quality still needs to be improved. Strengthened training for clinicians and pharmacists and the prompt establishment of a multidimensional “efficacy-dose-safety” evaluation system are warranted to further ensure safe and rational medication. |
| Key words: methylphenidate hydrochloride extended-release tablets attention deficit hyperactivity disorder prescription rationality children’s drug utilization index |
